ArticleCardiovascular diabetology2023
Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease.
Article in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04619277 (Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Clinical application and expansion of paclitaxel-coated balloons in coronary atherosclerotic disease.World journal of cardiology · 2026Review
- Recent advances in percutaneous coronary intervention for modernizing coronary physiology-guided and device-based strategies for coronary revascularization.Frontiers in medicine · 2026Review
- Drug-coated balloon vs drug-eluting stent in de novo coronary lesions: a propensity score matched cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Contemporary Percutaneous Coronary Intervention in Diabetic Patients.Reviews in cardiovascular medicine · 2025Review
- Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.Current treatment options in cardiovascular medicine · 2025Article
- Drug-Coated Balloon-Based Intervention for De Novo Acute Myocardial Infarction.Yonsei medical journal · 2025Observational
- Drug-coated balloons and diabetes: a review.Cardiovascular diabetology · 2025Review
- Blended Coronary Revascularization with Drug-Coated Balloon and Drug-Eluting Stent: A Narrative Review on Rationale, Clinical Evidence, and Future Perspectives.Journal of clinical medicine · 2025Review
- Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand.Journal of clinical medicine · 2025Review
- Drug-Coated Balloons-Based Intervention for Coronary Artery Disease: The Second Report of Asia-Pacific Consensus Group.JACC. Asia · 2025Review
- Application of Drug-Coated Balloons in Complex High Risk and Indicated Percutaneous Coronary Interventions.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Review
- A Prospective Randomized Trial Comparing 2 Different Paclitaxel-Coated Balloons in De Novo Coronary Artery Disease.JACC. Asia · 2025Article
- Contemporary Use of Drug-Coated Balloons for Coronary Angioplasty: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Drug-Coated Balloon Treatment for De Novo Coronary Lesions: Current Status and Future Perspectives.Korean circulation journal · 2024Review
- Drug-coated balloon angioplasty with provisional stenting versus primary stenting for the treatment of de novo coronary artery lesions: REC-CAGEFREE I trial rationale and design.BMC cardiovascular disorders · 2024Article
- Factors influencing coronary artery target lesion revascularization after drug-coated balloon angioplasty.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on drug-coated balloon (DCB) treatment in the context of diabetes mellitus (DM) and multivessel coronary artery disease (CAD) are limited. We aimed to investigate the clinical impact of DCB-based revascularization on percutaneous coronary intervention (PCI) in patients with DM and multivessel CAD.
methodsA total of 254 patients with multivessel disease (104 patients with DM) successfully treated with DCB alone or combined with drug-eluting stent (DES) were retrospectively enrolled (DCB-based group) and compared with 254 propensity-matched patients treated with second-generation DES from the PTRG-DES registry (n = 13,160 patients) (DES-only group). Major adverse cardiovascular events (MACE) comprised cardiac death, myocardial infarction, stroke, stent or target lesion thrombosis, target vessel revascularization, and major bleeding at 2 years.
resultsThe DCB-based group was associated with a reduced risk of MACE in patients with DM (hazard ratio [HR] 0.19, 95% confidence interval [CI] 0.05-0.68, p = 0.003], but not in those without DM (HR 0.52, 95% CI 0.20-1.38, p = 0.167) at the 2-year follow-up. In patients with DM, the risk of cardiac death was lower in the DCB-based group than the DES-only group, but not in those without DM. In both patients with or without DM, the burdens of DES and small DES (less than 2.5 mm) used were lower in the DCB-based group than in the DES-only group.
conclusionsIn multivessel CAD, the clinical benefit of a DCB-based revascularization strategy appears to be more evident in patients with DM than in those without DM after 2 years of follow-up. (Impact of Drug-Coated Balloon Treatment in De Novo Coronary Lesion; NCT04619277).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.